| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/10/2007 | US7241771 Prepared by dissolving 42-O-(2-hydroxy)ethyl-rapamycin in a solution containing an organic solvent and an aqueous buffer having a pH of 4 to 10; and extracting the SDZ-RAD Isomer C into an organic solvent; immunosuppressive, anti-inflammatory, antifungal, antiproliferative and antitumor agents |
| 07/10/2007 | US7241770 Hydronopol derivatives as agonists on human ORL1 receptors |
| 07/10/2007 | US7241769 Pyrimidines as PLK inhibitors |
| 07/10/2007 | US7241767 And thiones, 1-substituted with a pyrazolyl(thio)carbonyl group, e.g., 6-Bromo-1-[[3-bromo-1-(3-chloro-2-pyridinyl)-1H-pyrazol-5-yl]carbonyl]-8-methyl-3-(1-methylethyl)-2,4(1H,3R)-quinazolinedione; especially for use in growing and stored agronomic crops |
| 07/10/2007 | US7241766 Methods of using phenolic guanidine sodium channel blockers |
| 07/10/2007 | US7241765 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
| 07/10/2007 | US7241764 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders |
| 07/10/2007 | US7241763 3-furanyl analogs of toxoflavine as kinase inhibitors |
| 07/10/2007 | US7241762 Administering racemic reboxetine or a salt thereof for inhibition of norepinephrine reuptake |
| 07/10/2007 | US7241761 Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups |
| 07/10/2007 | US7241760 Central nervous system disorders; psycholgical disorders; antiepi;eptic agents; schizophrenia; Alzheimer's disease; cognition activators; analgesics |
| 07/10/2007 | US7241759 Cholecystokinin receptors as modulators to mediate diseases and gastrointestinal disorders |
| 07/10/2007 | US7241758 Aromatic compounds containing urea or thiourea groups are useful for terating cytokine mediated diseases |
| 07/10/2007 | US7241757 Amidino derivatives and their use as thrombin inhibitors |
| 07/10/2007 | US7241756 Containing 5-[4-[2[(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a salt for treating non-insulin dependent diabetes with improved blood glucose regulation without introducing unacceptable side-effects |
| 07/10/2007 | US7241755 E.g., pentamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-aza-13(Z)-cyclohexadecene-2,6-dione and 4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-dihydroxy-5,5,7,9,13,16-hexamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-oxa-13-cyclohexadecene-2,6-dione; antiproliferative agents |
| 07/10/2007 | US7241754 2-Desmethyl ansamycin compounds |
| 07/10/2007 | US7241753 Method of treatment of prostate cancer |
| 07/10/2007 | US7241752 17,20(E)-dehydro vitamin D analogs and their uses |
| 07/10/2007 | US7241751 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and its uses |
| 07/10/2007 | US7241750 2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses |
| 07/10/2007 | US7241749 2 Alpha-methyl-19,26,27-trinor-(20S)-1-alpha-hydroxyvitamin D3 and protected derivatives; arrests the proliferation of undifferentiated cells and induces their differentiation to monocytes; treating cancer, skin disorders, autoimmune disorders, inflammatory conditions, obesity and renal osteodystrophy |
| 07/10/2007 | US7241748 Especially 17(Z)-1 alpha ,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3; arrests the proliferation of undifferentiated cells and induces their differentiation to monocytes; treating cancer, skin disorders, autoimmune disorders, inflammatory conditions, and renal osteodystrophy |
| 07/10/2007 | US7241747 For therapy and prophylaxis of diseases where bone formation is desired, such as osteoporosis, as well as autoimmune diseases such as multiple sclerosis, diabetes mellitus and lupus; also exhibit pronounced activity in arresting the proliferation of undifferentiated cells |
| 07/10/2007 | US7241746 contains misoprostol, a tetracycline (doxycycline), an aminoglycoside (gentamicin), a fluoroquinoline (ciprofloxacin), a lincomycin (clindamycin), a macrolide (clarithromycin), an azalide (azithromycin), and an imidazole (metronidazole) |
| 07/10/2007 | US7241745 Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives |
| 07/10/2007 | US7241744 Delivering into cells of the subject an effective amount of a nucleic acid expression construct that encodes a growth-hormone-releasing-hormone ("GHRH") or functional biological equivalent thereof for therapy of anemia |
| 07/10/2007 | US7241743 Sir2α-based therapeutic and prophylactic methods |
| 07/10/2007 | US7241741 Respiratory system disorders ; concurrent administering fungicides, bactericides |
| 07/10/2007 | US7241736 spider, silkworm or other silk as a fibrosing agent; induce adhesion or fibrosis in the walls of the diverticula or facilitate "filling" of the diverticula in situ; thus obliterating the lumen of the diverticula and relieving symptoms |
| 07/10/2007 | US7241731 Oligopeptides for promoting hair growth |
| 07/10/2007 | US7241619 Identification of genes encoding enzymes (Thraustochytrium aureum Delta 5-desaturase, Saprolegnia diclina Delta 5-desaturase, Saprolegnia diclina Delta 6-desaturase)involved in synthesis of polyunsaturated fatty acids |
| 07/10/2007 | US7241618 A polynucleotide comprising a RNA polymerase promoter, able encoding a siRNA; treating cancer and genetic disorders; genetic engineering, inhibit gene expression of a target gene |
| 07/10/2007 | US7241617 Transferring nucleic acids into nerve cells; mix cell and vector, incubate, recover transformed nerve cells |
| 07/10/2007 | US7241591 Adenovirus comprising a gene coding for glutathione peroxidase |
| 07/10/2007 | US7241571 Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis |
| 07/10/2007 | US7241468 Cooking oil, baking oil comprising sucrose fatty acid ester and triglycerides with long chain, medium chain or mixed fatty acids; nongreasy, dietetics |
| 07/10/2007 | US7241460 Strontium compound for treatment of sub-dermal soft tissue pain |
| 07/10/2007 | US7241459 Bactericidal and fungicidal glass activated by moisture comprising oxides of silicon, calcium and phosphorus;nontoxic; no side effects; packaging; food processing;seals; clothing; medical equipment; automobiles; construction materials; coatings |
| 07/10/2007 | US7241458 Antiviral compositions |
| 07/10/2007 | US7241456 Formulations for topical delivery of bioactive substances and methods for their use |
| 07/10/2007 | US7241454 Mixture containing nonionic surfactants; uniform viscosity |
| 07/10/2007 | US7241445 Human monoclonal antibody against hepatitis C virus E2 glycoprotein |
| 07/10/2007 | US7241282 Compositions and methods for prolonging survival of platelets |
| 07/10/2007 | US7240785 Method and apparatus for transferring substrates |
| 07/10/2007 | CA2466340C Farnesyl dibenzodiazepinone, processes for its production and its use as a pharmaceutical |
| 07/10/2007 | CA2441461C Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia |
| 07/10/2007 | CA2427815C Controlled release hydrocodone formulations |
| 07/10/2007 | CA2421910C Xanthine phosphodiesterase v inhibitors |
| 07/10/2007 | CA2396814C Novel 1,3-dihydro-2h-indol-2-one derivatives, preparation method and pharmaceutical compositions containing them |
| 07/10/2007 | CA2380072C Nicotine in therapeutic angiogenesis and vasculogenesis |
| 07/10/2007 | CA2378628C New indenoindolone derivatives, the process for preparing them and the pharmaceutical compounds that contain them |
| 07/10/2007 | CA2367092C Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| 07/10/2007 | CA2308850C Inhibitors of gap junction communication |
| 07/10/2007 | CA2301852C Angiogenesis promoters and angiogenesis potentiators |
| 07/10/2007 | CA2283564C Pharmaceutical compositions having appetite suppressant activity |
| 07/10/2007 | CA2260756C System for genetically treating cardiac conduction disturbances |
| 07/10/2007 | CA2245506C Granules from triazines |
| 07/10/2007 | CA2200991C Compounds for the suppression of hiv tat transactivation |
| 07/10/2007 | CA2199401C Pyrimido[5,4-d]pyrimidines, medicaments comprising these compounds, their use and processes for their preparation |
| 07/10/2007 | CA2194462C Hard tissue stimulating agent |
| 07/10/2007 | CA2190807C Acetylsalicylic acid and tocopherol stable pharmaceutical composition |
| 07/10/2007 | CA2184461C A method for inhibiting an irregular binding of human lens cells |
| 07/10/2007 | CA2161652C Topical compositions for re-epitheliazation of persistent epithelial defects |
| 07/10/2007 | CA2135710C Melatonin derivatives for use in treating desynchronization disorders |
| 07/10/2007 | CA2128706C Polyunsaturated fatty acid based drugs, in particular docosahexaenoic acid, as platelet aggregation inhibitors and against essential fatty acid deficiencies of the brain |
| 07/10/2007 | CA2124769C Recombinant foamy virus vectors for medicinal and diagnostic uses, and processes for preparing recombinant foamy virus vectors |
| 07/10/2007 | CA2121324C Cephalosporin derivatives |
| 07/10/2007 | CA2108466C Hcv genomic sequences for diagnostics and therapeutics |
| 07/10/2007 | CA2098849C Control of gene expression by ionizing radiation |
| 07/10/2007 | CA2087818C Oligonucleotide analogs, their preparation and use |
| 07/09/2007 | CA2635370A1 Modulators of hypoxia inducible factor-1 and related uses |
| 07/06/2007 | CA2532283A1 Drug formulation for mouth or pharynx comprising local anesthetic |
| 07/05/2007 | WO2007076555A2 A location based wireless collaborative environment with a visual user interface |
| 07/05/2007 | WO2007076531A1 Compositions and methods for preventing or treating inflammatory bowel disease |
| 07/05/2007 | WO2007076505A2 Transferrin and transferrin-based compositions for diabetes treatment |
| 07/05/2007 | WO2007076474A1 Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| 07/05/2007 | WO2007076467A2 Use of anecortave acetate as an adjunct during filtration bleb surgery |
| 07/05/2007 | WO2007076454A1 Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| 07/05/2007 | WO2007076448A2 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| 07/05/2007 | WO2007076444A2 Improved oral compositions comprising zinc citrate and/or tocopherol agents |
| 07/05/2007 | WO2007076431A1 Macrocyclic factor viia inhibitors useful as anticoagulants |
| 07/05/2007 | WO2007076423A2 INHIBITORS OF Akt ACTIVITY |
| 07/05/2007 | WO2007076413A2 Antimicrobial durable medical equipment |
| 07/05/2007 | WO2007076387A1 Phytosterols for use in reducing c-reactive protein levels |
| 07/05/2007 | WO2007076379A2 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions |
| 07/05/2007 | WO2007076372A2 Treatment of neuroaids using inhibitors of glycogen synthase kinase (gsk)-3 |
| 07/05/2007 | WO2007076365A2 Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection |
| 07/05/2007 | WO2007076360A1 (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions |
| 07/05/2007 | WO2007076348A2 Azaindole inhibitors of aurora kinases |
| 07/05/2007 | WO2007076345A2 Synthesis of epirubicin from 13-dihydrodaunorubicine |
| 07/05/2007 | WO2007076328A2 Rna interference mediated inhibition of hepatitis c virus |
| 07/05/2007 | WO2007076323A2 Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof |
| 07/05/2007 | WO2007076322A2 Compositions and methods for attenuating mitochondria-mediated cell injury |
| 07/05/2007 | WO2007076320A2 Compounds |
| 07/05/2007 | WO2007076318A2 Camphor-derived cxcr3 antagonists |
| 07/05/2007 | WO2007076310A2 Iontophoretic transdermal delivery of nicotine salts |
| 07/05/2007 | WO2007076306A1 Fluorinated compounds |
| 07/05/2007 | WO2007076286A2 Chemical compounds |
| 07/05/2007 | WO2007076266A2 Therapeutic formulation |